Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)

NCT07668414 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07668414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07668414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Recruiting
Start date
September 22, 2026
Completion date
October 10, 2028
Enrollment
650 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight